Business
Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research
Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, March 18, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, March 18, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it is offering its High Throughput Screening (HTS) facility, in order to assist with  the Israeli national effort in researching and containing SARS-CoV-2.\n\n \n  \n\n \nThe company is currently evaluating its abilities in High Throughput Screening for identifying potential inhibitors of the Corona virus. The company estimates that it could potentially contribute from its capabilities and knowledge in order to support the ongoing national effort on two levels: establish and operate a diagnostic platform and screen libraries of compounds in High Throughput Screening (HTS) such as cannabinoids, combinations of FDA antiviral approved drugs, and natural products.\nDue to the circumstances, the company is willing to establish these operations, while taking into consideration necessary regulations, safety issues, availability of reagents, and availability of samples - HCoV OC43 (virus model).\nAbout Cannabics Pharmaceuticals\nCannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S public company that is developing a platform that leverages novel drug-screening tools to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on...